NDC 50419-344
Ultravist
Iopromide
Ultravist is a Intra-arterial; Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Bayer Healthcare Pharmaceuticals Inc.. The primary component is Iopromide.
| Product ID | 50419-344_1082cd73-403a-4109-a036-25097e2064c1 |
| NDC | 50419-344 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Ultravist |
| Generic Name | Iopromide |
| Dosage Form | Injection |
| Route of Administration | INTRA-ARTERIAL; INTRAVENOUS |
| Marketing Start Date | 2009-12-30 |
| Marketing Category | NDA / NDA |
| Application Number | NDA020220 |
| Labeler Name | Bayer HealthCare Pharmaceuticals Inc. |
| Substance Name | IOPROMIDE |
| Active Ingredient Strength | 300 mg/mL |
| Pharm Classes | Radiographic Contrast Agent [EPC], X-Ray Contrast Activity [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 50419-344-05
10 VIAL, GLASS in 1 CARTON (50419-344-05) > 50 mL in 1 VIAL, GLASS
| Marketing Start Date | 2009-12-30 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 50419-344-91 [50419034491]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2016-10-11 |
NDC 50419-344-05 [50419034405]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-13 [50419034413]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2009-09-24 |
| Marketing End Date | 2010-05-05 |
NDC 50419-344-97 [50419034497]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2016-10-11 |
NDC 50419-344-21 [50419034421]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-19 [50419034419]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2009-09-23 |
| Marketing End Date | 2010-05-05 |
NDC 50419-344-65 [50419034465]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2018-05-04 |
NDC 50419-344-43 [50419034443]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-48 [50419034448]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-50 [50419034450]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
| Marketing End Date | 2010-05-05 |
NDC 50419-344-10 [50419034410]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-07 [50419034407]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
| Marketing End Date | 2017-07-27 |
NDC 50419-344-15 [50419034415]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-12 [50419034412]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-32 [50419034432]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2015-10-11 |
NDC 50419-344-58 [50419034458]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-41 [50419034441]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA020220 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2009-12-30 |
NDC 50419-344-23 [50419034423]
Ultravist INJECTION
| Marketing Category | NDA |
| Application Number | NDA021425 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2018-05-04 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| IOPROMIDE | 300 mg/mL |
OpenFDA Data
| SPL SET ID: | 65647318-27e4-4f37-bd68-50eea52d6c5b |
| Manufacturer | |
| UNII |
Pharmacological Class
- Radiographic Contrast Agent [EPC]
- X-Ray Contrast Activity [MoA]
NDC Crossover Matching brand name "Ultravist" or generic name "Iopromide"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 50419-342 | Ultravist | iopromide |
| 50419-344 | Ultravist | iopromide |
| 50419-346 | Ultravist | iopromide |
Trademark Results [Ultravist]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ULTRAVIST 73708062 1542191 Live/Registered |
SCHERING AG, BERLIN AND BERGKAMEN 1988-03-10 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.